2023
DOI: 10.3390/cancers15164026
|View full text |Cite
|
Sign up to set email alerts
|

BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers

Abstract: Melanoma is an aggressive form of skin cancer resulting from the malignant transformation of melanocytes. Recent therapeutic approaches, including targeted therapy and immunotherapy, have improved the prognosis and outcome of melanoma patients. BRAF is one of the most frequently mutated oncogenes recognised in melanoma. The most frequent oncogenic BRAF mutations consist of a single point mutation at codon 600 (mostly V600E) that leads to constitutive activation of the BRAF/MEK/ERK (MAPK) signalling pathway. Th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
13
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 39 publications
(13 citation statements)
references
References 227 publications
0
13
0
Order By: Relevance
“…The most frequent oncogenic BRAF mutations consist of a single point mutation at codon 600 (mostly V600E) that leads to the constitutive activation of the BRAF/MEK/ERK (MAPK) signaling pathway. Therefore, mutated BRAF has become a useful target for molecular therapy and the use of BRAF kinase inhibitors has shown promising results …”
Section: Therapeutic Strategies For the Treatment Of Skin Cancermentioning
confidence: 99%
See 1 more Smart Citation
“…The most frequent oncogenic BRAF mutations consist of a single point mutation at codon 600 (mostly V600E) that leads to the constitutive activation of the BRAF/MEK/ERK (MAPK) signaling pathway. Therefore, mutated BRAF has become a useful target for molecular therapy and the use of BRAF kinase inhibitors has shown promising results …”
Section: Therapeutic Strategies For the Treatment Of Skin Cancermentioning
confidence: 99%
“…Therefore, mutated BRAF has become a useful target for molecular therapy and the use of BRAF kinase inhibitors has shown promising results. 226 …”
Section: Therapeutic Strategies For the Treatment Of Skin Cancermentioning
confidence: 99%
“…Typically, BRAF is involved in either homo- or heterodimerization with another RAF kinase in response to growth signals, playing a vital role in regulating cellular growth and proliferation [ 39 ]. However, mutations in the BRAF gene, which substitutes valine with glutamic acid, can result in a 480-fold increase in BRAF kinase activation [ 40 ]. This hyperactivation results in continuous stimulation of the MAPK pathway, leading to unchecked cell proliferation and survival.…”
Section: Melanomamentioning
confidence: 99%
“…1 B). The vicarious modulation of components of the multi-cellular network (MCN) in the TME can be achieved by small molecules that activate multiple anti-tumoral mechanisms [ 3 ] that we refer to as ‘smart’ small molecules, pathway inhibitors [ 4 ], biologics such as ADCs [ 5 , 6 ], chimeric antigen receptors (CAR) T cells or tumor infiltrating lymphocytes (TIL) [ 7 ] and genetic engineering modalities such as polycistronic mRNA or DNA constructs that can simultaneously deliver pleiotropic payloads [ 8 ]. Such modalities can result in amplification of anti-cancer responses through the secondary engagement of endogenous immune effector functions.…”
Section: Direct (Primary) Versus Indirect (Secondary) Cancer Cell Kil...mentioning
confidence: 99%
“…Unless the treatment can eliminate all cancer cells at the first round, likelihood of recurrence through expansion of therapy-resistant clones is high and long-term benefit unlikely. This is because, cancer is a fast-track evolutionary process that rapidly adapts to environmental pressure by making the target irrelevant either by losing its expression as is the case for tumor-associated antigens (Ags) [ 21 ] or by circumventing its oncogenic properties in the case of pathway inhibitors [ 4 ] by acquiring alternative oncogenic mechanisms (Fig. 1 A).…”
Section: Direct (Primary) Versus Indirect (Secondary) Cancer Cell Kil...mentioning
confidence: 99%